Hadassah Medical Center has achieved a significant milestone, receiving international recognition as Israel’s inaugural center of excellence in cardio-oncology. This recognition comes at a crucial time, given the ongoing academic boycotts against Israel. Led by Prof. Dan Gilon, the Hadassah Cardio-Oncology Center has been acknowledged by the International Cardio-Oncology Society (ICOS), marking a noteworthy achievement for the medical community in Israel.

The field of cardio-oncology, which explores the intricate relationship between heart disease and cancer, has witnessed global development, particularly in Israel over the past decade. This progress is driven by an increasing number of patients with extended life expectancies and improved cancer treatment success rates. However, these treatments can pose potential risks to cardiovascular health, arising from factors such as heart disease, treatment side effects, or the use of chemotherapy and biological drugs.

With over 250 patients treated annually, the Hadassah Cardio-Oncology Center addresses these challenges through a multidisciplinary approach, fostering collaboration between cardiology, oncology, and hematology. Prof. Dan Gilon emphasizes the importance of raising awareness among patients and healthcare professionals, advocating for optimal treatment through coordinated efforts.

The official recognition by ICOS, especially amidst international boycotts, underscores the center’s commitment to advancing medical knowledge and patient care. Established a decade ago, the center’s success is attributed to the collective support from the cardiology, oncology, and hematology departments.

Prof. Gilon highlights the continuous growth of the field, serving a community of approximately 400,000 people in Israel, including cancer patients and survivors at higher risk of heart disease. The Hadassah Cardio-Oncology Center not only provides essential care but also pioneers education, being the first in Israel to incorporate cardio-oncology into the cardiology curriculum for medical students.

In the face of the ongoing war, Prof. Yoram Weiss, Director General of Hadassah, emphasizes the significance of ICOS’s recognition. He sees it as an affirmation that research, science, and health transcend conflicts, recognizing the enduring international contributions of Israeli medical activities. This recognition reflects Hadassah’s commitment to excellence, driving positive change within the Israeli and global health systems.